Lessons from the Stroke Prevention in Atrial Fibrillation Trials

Annals of Internal Medicine

Volumn 138, Issue 10, 2003, Pages 831-838

  Hart, Robert G ^a   Halperin, Jonathan L ^b   Pearce, Lesly A ^b   Anderson, David C ^b   Kronmal, Richard A ^b   McBride, Ruth ^b   Nasco, Elaine ^b   Sherman, David G ^b   Talbert, Robert L ^b   Marler, John R ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; PATIENT MONITORING; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; STROKE; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CEREBROVASCULAR ACCIDENT; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; WARFARIN;

EID: 0038010705     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-138-10-200305200-00011     Document Type: Review

References (47)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-5. [PMID: 11343485]
2. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33. [PMID: 12466506]
3. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med. 1990;322:863-8. [PMID: 2407959]
4. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991; 84:527-39. [PMID: 1860198]
5. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-91. [PMID: 7907677]
6. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633-8. [PMID: 8782752]
7. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA. 1998;279:1273-7. [PMID: 9565007]
8. Anderson DC, Kappelle LJ, Eliasziw M, Babikian VL, Pearce LA, Barnett HJ. Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis. Stroke. 2002;33:1963-7. [PMID: 12154246]
9. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation. 2002;106:1962-7. [PMID: 12370220]
10. van Walraven C, Hart RG, Petersen P, Koudstaal PJ, Gullov AL, Hellemons BS, et al. A clinical decision rule to identify patients with atrial fibrillation who have a low stroke risk while taking aspirin. Arch Intern Med. 2003; [In press].
11. Gage BF, van Walraven C, Pearce LA, Hart RG, Koudstaal PJ, Hellemons BSP, et al. Selecting patients with atria] fibrillation for anticoagulation: validation of risk stratification schemes [Abstract]. J Gen Intern Med. 2003; [In press].
12. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA. 2002;288:2441-8. [PMID: 12435257]
13. Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. The Stroke Prevention in Atrial Fibrillation Investigators. Stroke. 1990;21:538-45. [PM[D: 2183405]
14. Stroke Prevention in Atrial Fibrillation Investigators. A differential effect of aspirin for prevention of stroke in atrial fibrillation. Journal of Stroke and Cerebrovascular Diseases. 1993;3:181-8.
15. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med. 1992;116:1-5. [PMID: 1727091]
16. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med. 1992;116:6-12. [PMID: 1727097]
17. Miller VT, Rothrock JF, Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators. Neurology. 1993;43:32-6. [PMID: 8423907]
18. Miller VT, Pearce LA, Feinberg WM, Rothrock JF, Anderson DC, Hart RG. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Neurology. 1996;46:238-40. [PMID: 8559383]
19. Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000;10:39-43. [PMID: 10629345]
20. Petersen P, Boysen G. Prevention of stroke in atrial fibrillation [Letter]. N Engl J Med. 1990;323:482.
21. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175-9. [PMID: 2563096]
22. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin compared to aspirin for prevention of arterial thromboembolism in arrial fibrillation: design and patient characteristics of the SPAF II Study. Cerebrovasc Dis. 1992;2:332-41.
23. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators, Arch Intern Med. 1996; 156:409-16. [PMID: 8607726]
24. Hellemons BS, Langenberg M, Lodder J, Vermeer F, Schouten HJ, Lemmens T, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999;319:958-64. [PMID: 10514159]
25. Singer DE, Hughes RA, Gress DR, Sheehan MA, Oertel LB, Maraventano SW, et al. The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study. Am Heart J. 1992;124:1567-73. [PMID: 1462916]
26. Kanter MC, Tegeler CH, Pearce LA, Weinberger J, Feinberg WM, Anderson DC, et al. Carotid stenosis in patients with atrial fibrillation. Prevalence, risk factors, and relationship to stroke in the Stroke Prevention in Atrial Fibrillation Study. Arch Intern Med. 1994;154:1372-7. [PMID: 8002689]
27. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Study. Journal of Stroke and Cerebrovascular Diseases. 1995;5:147-57.
28. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70. [PMID: 11401607]
29. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993;342:1255-62. [PMID: 7901582]
30. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-57. [PMID: 8018000]
31. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation III study: rationale, design, and patient features. Journal of Stroke and Cerebrovascular Diseases. 1997;5:341-53.
32. Feinberg WM, Kronmal RA, Newman AB, Kraut MA, Bovill EG, Cooper L, et al. Stroke risk in an elderly population with atrial fibrillation. J Gen Intern Med. 1999;14:56-9. [PMID: 9893092]
33. Pearce LA, Hart RG, Halperin JL. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. Am J Med. 2000; 109:45-51. [PMID: 10936477]
34. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 2000;35:183-7. [PMID: 10636278]
35. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999;30:1223-9. [PMID: 10356104]
36. Transesophageal echocardiography in atrial fibrillation: standards for acquisition and interpretation and assessment of interobserver variability. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. J Am Soc Echocardiogr. 1996;9:556-66. [PMID: 8827639]
37. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med. 1998;128:639-47. [PMID: 9537937]
38. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr. 1999; 12:1080-7. [PMID: 10588784]
39. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998;31:1622-6. [PMID: 9626843]
40. Asinger RW, Koehler J, Pearce LA, Zabalgoitia M, Blackshear JL, Fenster PE, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echocardiographic contrast (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study). J Am Soc Echocardiogr. 1999; 12:1088-96. [PMID: 10588785]
41. Blackshear JL, Pearce LA, Hart RG, Zabalgoitia M, Labovitz A, Asinger RW, et al. Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke. 1999;30:834-40. [PMID: 10187888]
42. Blackshear JL, Zabalgoitia M, Pennock G, Fenster P, Strauss R, Halperin J, et al. Warfarin safety and efficacy in patients with thoracic aottic plaque and atrial fibrillation. SPAF TEE Investigators. Stroke Prevention and Atrial Fibrillation. Transesophageal echocardiography. Am J Cardiol. 1999;83:453-5, A9. [PMID: 10072242]
43. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501. [PMID: 10507957]
44. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med. 1997;157:1237-40. [PMID: 9183235]
45. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med. 1998; 158:1316-20. [PMID: 9645825]
46. Go AS, Hylek EM, Phillips KA, Borowsky LH, Henault LE, Chang Y, et al. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 2000;102:11-3. [PMID: 10880408]
47. Petersen P. Long-term treatment of patients using the new oral direct thrombin inhibitor ximelagatran versus warfarin in moderate to high stroke risk patients with atrial fibrillation [Abstract]. Journal of the Neurological Sciences. 2000; 187(Suppl 1):S124-5.